MITSUBISHI - PHASE 3 OF THE PHASE 2/3 CLINICAL TRIAL OF THE NOVEL CORONAVIRUS INFECTION VACCINE CANDIDATE MT-2766, CONFIRMING GOOD EFFICACY AND SAFETY IN AN ENVIRONMENT WHERE MUTANTS ARE DOMINANT

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka, President and CEO: Hiroaki Ueno, hereinafter referred to as 'the Company') is a plant-derived viral particle (Virus Like Particle, hereinafter referred to as 'VLP') developed by its consolidated subsidiary Medicago Co., Ltd. to prevent covid-19.

We are pleased to announce that we have confirmed the good efficacy and safety of phase 3 of the Phase 2/3 clinical trial of vaccines (development number: MT-2766) in collaboration with GlaxoSmithKline ( Headquartered in London, UK, GSK). The MT-2766 is used in conjunction with GSK's pandemic adjuvant.

Contact:

Tel: [phone]

(C) 2021 Electronic News Publishing, source ENP Newswire